Crystal structure of brigatinib Form A (Alunbrig®), C 29 H 39 ClN 7 O 2 P
Source abstract
Abstract
The crystal structure of brigatinib Form A has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Brigatinib Form A crystallizes in space group P -1 (#2) with a = 9.59616(20), b = 10.9351(3), c = 14.9913(6) Å, α = 76.1210(13), β = 79.9082(11), γ = 74.0802(6)°, V = 1458.497(15) Å 3 , and Z = 2. Structure solution was complicated by the lowest cost factor solution having an unreasonable conformation of the dimethylphosphoryl group. The second-best structure yielded a better refinement. The crystal structure is characterized by alternating layers of aliphatic and aromatic portions of the molecules along the b -axis. Strong N–H⋯N hydrogen bonds link the molecules into pairs, with a graph set R 2,2(8). There is a strong intramolecular N–H⋯O hydrogen bond to the phosphoryl group, which determines the orientation of this group. The powder pattern has been submitted to ICDD® for inclusion in the Powder Diffraction File™ (PDF®).
Source: crossref · Quality: baseline
Research context
OpenAlex topics: X-ray Diffraction in Crystallography · Multicomponent Synthesis of Heterocycles · Synthesis and Characterization of Heterocyclic Compounds
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. 10.1063/1.296926010.1063/1.2969260 ↗
2. 10.1002/qua.2465810.1002/qua.24658 ↗
3. Rozamus, L. W. (2016). “Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine,” International Patent Application WO 2016/065028 A1.
4. Wavefunction, Inc. (2018). Spartan ‘18 Version 1.2.0, Wavefunction Inc., 18401 Von Karman Ave., Suite 370, Irvine, CA 92612.
5. 2021
6. 10.1021/ci049780b10.1021/ci049780b ↗
7. 10.1056/NEJMoa181017110.1056/NEJMoa1810171 ↗
8. Bravais · 1866
9. 10.1093/nar/gkaa97110.1093/nar/gkaa971 ↗
10. 10.1107/S002188980201523610.1107/S0021889802015236 ↗
11. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
12. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
13. 10.1017/S088571561800082910.1017/S0885715618000829 ↗
14. 10.1002/anie.19951555110.1002/anie.199515551 ↗
15. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
16. Turner · 2017
17. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
18. 2021
19. 2013
20. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
21. 10.1007/BF0054909610.1007/BF00549096 ↗
22. Martin, N. (2019). “Pharmaceutical composition of brigatinib,” International Patent Application WO 2019/158421 A1.
23. Etudes sur la loi de Bravais
24. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
25. 10.1107/S010876819901508610.1107/S0108768199015086 ↗
26. A new law of crystal morphology extending the law of Bravais
27. 10.1063/1.46788210.1063/1.467882 ↗
28. 10.1017/S088571561900081210.1017/S0885715619000812 ↗
29. Open Babel: an open chemical toolbox
30. 10.1002/jcc.2315310.1002/jcc.23153 ↗
31. 10.1021/ar00172a00510.1021/ar00172a005 ↗
32. 10.1107/S002188981300353110.1107/S0021889813003531 ↗